223 related articles for article (PubMed ID: 32557557)
1. Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?
Sousa LP; Pinho V; Teixeira MM
Br J Pharmacol; 2020 Sep; 177(17):3898-3904. PubMed ID: 32557557
[TBL] [Abstract][Full Text] [Related]
2. Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7).
Tavares LP; Melo EM; Sousa LP; Teixeira MM
Semin Immunol; 2022 Jan; 59():101601. PubMed ID: 35219595
[TBL] [Abstract][Full Text] [Related]
3. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
4. The resolution of acute inflammation induced by cyclic AMP is dependent on annexin A1.
Lima KM; Vago JP; Caux TR; Negreiros-Lima GL; Sugimoto MA; Tavares LP; Arribada RG; Carmo AAF; Galvão I; Costa BRC; Soriani FM; Pinho V; Solito E; Perretti M; Teixeira MM; Sousa LP
J Biol Chem; 2017 Aug; 292(33):13758-13773. PubMed ID: 28655761
[TBL] [Abstract][Full Text] [Related]
5. Roles of resolvins in the resolution of acute inflammation.
Qu Q; Xuan W; Fan GH
Cell Biol Int; 2015 Jan; 39(1):3-22. PubMed ID: 25052386
[TBL] [Abstract][Full Text] [Related]
6. Annexin A1 promotes timely resolution of inflammation in murine gout.
Galvão I; Vago JP; Barroso LC; Tavares LP; Queiroz-Junior CM; Costa VV; Carneiro FS; Ferreira TP; Silva PM; Amaral FA; Sousa LP; Teixeira MM
Eur J Immunol; 2017 Mar; 47(3):585-596. PubMed ID: 27995621
[TBL] [Abstract][Full Text] [Related]
7. Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential.
Li QF; Hao H; Tu WS; Guo N; Zhou XY
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7442-7453. PubMed ID: 32706084
[TBL] [Abstract][Full Text] [Related]
8. Specialized pro-resolving lipid mediators and resolution of viral diseases.
Ferri G; Mucci M; Mattoscio D; Recchiuti A
Prostaglandins Other Lipid Mediat; 2023 Oct; 168():106762. PubMed ID: 37355222
[TBL] [Abstract][Full Text] [Related]
9. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation.
Perretti M; Dalli J
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():449-469. PubMed ID: 36151051
[TBL] [Abstract][Full Text] [Related]
10. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation.
Radbakhsh S; Katsiki N; Santos RD; Mikhailidis DP; Mantzoros CS; Sahebkar A
Metabolism; 2022 Jul; 132():155211. PubMed ID: 35533891
[TBL] [Abstract][Full Text] [Related]
11. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
Gigante A; Aquili A; Farinelli L; Caraffa A; Ronconi G; Enrica Gallenga C; Tetè G; Kritas SK; Conti P
Med Hypotheses; 2020 Oct; 143():109856. PubMed ID: 32460208
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases.
Vago JP; Tavares LP; Riccardi C; Teixeira MM; Sousa LP
Biomed Pharmacother; 2021 Jan; 133():111033. PubMed ID: 33378946
[TBL] [Abstract][Full Text] [Related]
13. Specialized proresolving mediators in infection and lung injury.
Sandhaus S; Swick AG
Biofactors; 2021 Jan; 47(1):6-18. PubMed ID: 33249673
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice.
Tavares LP; Garcia CC; Vago JP; Queiroz-Junior CM; Galvão I; David BA; Rachid MA; Silva PM; Russo RC; Teixeira MM; Sousa LP
Am J Respir Cell Mol Biol; 2016 Jul; 55(1):24-34. PubMed ID: 26677751
[TBL] [Abstract][Full Text] [Related]
15. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
16. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
Manolis AS; Manolis TA; Manolis AA; Melita H
J Cardiovasc Pharmacol; 2020 Oct; 76(4):397-406. PubMed ID: 32769760
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological strategies to resolve acute inflammation.
Sousa LP; Alessandri AL; Pinho V; Teixeira MM
Curr Opin Pharmacol; 2013 Aug; 13(4):625-31. PubMed ID: 23578762
[TBL] [Abstract][Full Text] [Related]
18. The resolution of inflammation: Principles and challenges.
Headland SE; Norling LV
Semin Immunol; 2015 May; 27(3):149-60. PubMed ID: 25911383
[TBL] [Abstract][Full Text] [Related]
19. As a potential treatment of COVID-19: Montelukast.
Fidan C; Aydoğdu A
Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
[TBL] [Abstract][Full Text] [Related]
20. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.
Serhan CN; Chiang N; Dalli J
Semin Immunol; 2015 May; 27(3):200-15. PubMed ID: 25857211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
